SH PHARMA Reports Stable Share Capital and Full Public-Float Compliance in May 2026

Bulletin Express06-01

Shanghai Pharmaceuticals Holding Co., Ltd. (SH PHARMA) disclosed its Monthly Return for the period ended 31 May 2026, confirming that no movements occurred in either its authorised or issued share capital during the month.

The group’s authorised share capital remains at 3.71 billion shares, split between 919.07 million H-shares and 2.79 billion A-shares, each with a par value of RMB 1.00.

Issued shares also stayed unchanged at 3.71 billion—comprising 919.07 million H-shares listed in Hong Kong and 2.79 billion A-shares listed in Shanghai. The company held no treasury shares as of month-end.

SH PHARMA confirmed that its H-share public float continues to satisfy the Hong Kong Stock Exchange’s minimum requirement—5 % of the total issued H-shares—demonstrating full regulatory compliance.

No share options, warrants, convertibles, or other equity instruments were issued, exercised, or cancelled during the reporting period, and no other equity movements were recorded.

The filing was signed by Joint Company Secretary Zhong Tao and submitted to Hong Kong Exchanges and Clearing Limited on 1 June 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1100604039?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-01 17:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1100604039","market":"us","top_or_hot":-1,"title":"SH PHARMA Reports Stable Share Capital and Full Public-Float Compliance in May 2026","media":"Bulletin Express","content":"<p>Shanghai Pharmaceuticals Holding Co., Ltd. (SH PHARMA) disclosed its Monthly Return for the period ended 31 May 2026, confirming that no movements occurred in either its authorised or issued share capital during the month.</p>\n<p>The group’s authorised share capital remains at 3.71 billion shares, split between 919.07 million H-shares and 2.79 billion A-shares, each with a par value of RMB 1.00.</p>\n<p>Issued shares also stayed unchanged at 3.71 billion—comprising 919.07 million H-shares listed in Hong Kong and 2.79 billion A-shares listed in Shanghai. The company held no treasury shares as of month-end.</p>\n<p>SH PHARMA confirmed that its H-share public float continues to satisfy the Hong Kong Stock Exchange’s minimum requirement—5 % of the total issued H-shares—demonstrating full regulatory compliance.</p>\n<p>No share options, warrants, convertibles, or other equity instruments were issued, exercised, or cancelled during the reporting period, and no other equity movements were recorded.</p>\n<p>The filing was signed by Joint Company Secretary Zhong Tao and submitted to Hong Kong Exchanges and Clearing Limited on 1 June 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SH PHARMA Reports Stable Share Capital and Full Public-Float Compliance in May 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSH PHARMA Reports Stable Share Capital and Full Public-Float Compliance in May 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-01 17:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Pharmaceuticals Holding Co., Ltd. (SH PHARMA) disclosed its Monthly Return for the period ended 31 May 2026, confirming that no movements occurred in either its authorised or issued share capital during the month.</p>\n<p>The group’s authorised share capital remains at 3.71 billion shares, split between 919.07 million H-shares and 2.79 billion A-shares, each with a par value of RMB 1.00.</p>\n<p>Issued shares also stayed unchanged at 3.71 billion—comprising 919.07 million H-shares listed in Hong Kong and 2.79 billion A-shares listed in Shanghai. The company held no treasury shares as of month-end.</p>\n<p>SH PHARMA confirmed that its H-share public float continues to satisfy the Hong Kong Stock Exchange’s minimum requirement—5 % of the total issued H-shares—demonstrating full regulatory compliance.</p>\n<p>No share options, warrants, convertibles, or other equity instruments were issued, exercised, or cancelled during the reporting period, and no other equity movements were recorded.</p>\n<p>The filing was signed by Joint Company Secretary Zhong Tao and submitted to Hong Kong Exchanges and Clearing Limited on 1 June 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02607","symbol_name":"上海医药","start_time":0,"source_url":"","article_id":"1100604039","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1100604039","pubTimestamp":1780307002,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Pharmaceuticals Holding Co., Ltd. (SH PHARMA) disclosed its Monthly Return for the period ended 31 May 2026, confirming that no movements occurred in either its authorised or issued share...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02607":"上海医药"},"translate_title":"上海医药报告2026年5月股本稳定且公众持股量全面合规","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02607":1},"content_text":"Shanghai Pharmaceuticals Holding Co., Ltd. (SH PHARMA) disclosed its Monthly Return for the period ended 31 May 2026, confirming that no movements occurred in either its authorised or issued share capital during the month.\nThe group’s authorised share capital remains at 3.71 billion shares, split between 919.07 million H-shares and 2.79 billion A-shares, each with a par value of RMB 1.00.\nIssued shares also stayed unchanged at 3.71 billion—comprising 919.07 million H-shares listed in Hong Kong and 2.79 billion A-shares listed in Shanghai. The company held no treasury shares as of month-end.\nSH PHARMA confirmed that its H-share public float continues to satisfy the Hong Kong Stock Exchange’s minimum requirement—5 % of the total issued H-shares—demonstrating full regulatory compliance.\nNo share options, warrants, convertibles, or other equity instruments were issued, exercised, or cancelled during the reporting period, and no other equity movements were recorded.\nThe filing was signed by Joint Company Secretary Zhong Tao and submitted to Hong Kong Exchanges and Clearing Limited on 1 June 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1100604039","isCrawlerRequest":true}